Loading
Life sciences · Journal article
Drug Testing and Analysis · August 14, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a method development study describing a precursor ion scan mass spectrometry approach to detect nitazenes in illicit drug samples. The method was tested on 25 control samples and then applied to 18 illicit samples where nitazenes were detected that had been missed by preliminary targeted analysis. The work is exploratory and demonstrates feasibility for a drug-checking tool but provides no evidence of clinical impact or prospective utility.
Uncontrolled method development and feasibility study. Drug samples (25 controls, 18 illicit) submitted to a community-level drug checking service; no demographic data on sample sources or users reported. Intervention: Precursor ion scan mass spectrometry method monitoring four common nitazene product ions with automated data interpretation tooling. Compared with: Preliminary targeted analysis (method and performance not specified).
Three nitazene compounds detected across 18 samples using precursor ion scan method where nitazenes were not previously detected by targeted analysis Nitazenes most commonly detected in place of expected pharmaceutical opioids, combined with benzodiazepines, and in complex opioid mixtures alongside fentanyl Method development and evaluation performed using 25 control samples at a community-level drug checking service
Nitazenes most commonly detected in place of expected pharmaceutical opioids, combined with benzodiazepines, and in complex opioid mixtures alongside fentanyl
This describes a screening tool that may improve harm reduction services by detecting emerging nitazenes in illicit drug supplies. The method has not been prospectively validated or tested for clinical utility in a real-world setting.
A method development study using 25 control samples and 18 illicit samples to demonstrate a screening tool for emerging drugs; lacks comparative validation, clinical outcomes, or prospective evidence of utility.
As stated by the source record.
Quoted from the source exactly as published.
This describes a screening tool that may improve harm reduction services by detecting emerging nitazenes in illicit drug supplies. The method has not been prospectively validated or tested for clinical utility in a real-world setting.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT The emergence of nitazene compounds in the illicit drug supply is a significant and increasing concern due to their high potency and rapid evolution in several parts of the world. Nitazenes create challenges for harm reduction drug checking services, where there is a need to provide relevant information about the composition of drug samples to people who use drugs. While targeted paper spray mass spectrometry has demonstrated abilities for drug checking, it is difficult to keep analysis methods up to date for the rapidly evolving drug supply. We have developed a precursor ion scan method that monitors four common nitazene product ions paired with tooling to streamline data interpretation. Twenty‐five control samples received at a community‐level drug checking service were used in method development and evaluation to ensure direct applicability to illicit drug samples. Using the developed method, three nitazene compounds, ‐pyrrolidino protonitazene, ‐desethyl etonitazene, and ‐pyrrolidino ethylene isotonitazene, were detected across 18 samples where a nitazene was not previously detected upon preliminary targeted analysis. This approach demonstrates rapid, nontargeted screening for the detection of emerging nitazenes, ultimately allowing more complete information about the composition of drug samples to be provided to people who use drugs, as well as public health monitoring and epidemiology. Data collected through drug checking service delivery found that nitazene compounds were most commonly detected in place of expected pharmaceutical opioids, combined with benzodiazepines, and in complex opioid mixtures alongside fentanyl. These findings highlight the wide‐ranging presence of nitazene compounds in the illicit drug supply.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.